Monoclonal Antibody Market: Size, Trend, Share, Opportunity Analysis, and Forecast 2014 - 2025

November 2018 | | ID: M5B3B3D5C37EN
Progressive Markets (owned by Antviews Global)

Abstracts

Monoclonal Antibody Market Overview:

The global monoclonal antibody market was valued at $76,899 million in 2014 and is estimated to reach $214,922 million by 2025, registering a CAGR of 9.8% from 2018 to 2025.

Monoclonal antibodies are identical immunoglobulins derived through cell division of a single parent cell. These antibodies are designed to recognize unique epitopes and bind to specific receptors found on the surface of cells. Owing to their property of monovalent affinity, monoclonal antibodies are used as therapeutic agents, diagnostic agents, protein purification agents, and others. The major therapeutic applications of monoclonal antibodies include cancer, autoimmune diseases, inflammatory diseases, infectious diseases, and others.

The global monoclonal antibody market is segmented based on source, indication type, sales channel, and region. Based on source, the market is segmented as humanized & human, chimeric, and murine. Based on indication type, the market is categorized as cancer, autoimmune disease, inflammatory diseases, neurology, and others. According to sales channel, the market is divided into hospital pharmacy, online provider, and retail pharmacy. Based on region, the market is studied across North America (U.S. and Rest of North America), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Market dynamics

Drivers

• Increase in demand of advanced therapeutics
• Growth in the prevalence of chronic diseases such as cancer, autoimmune disease, inflammatory disease, etc.

Restraint

• Higher cost of monoclonal antibody

Opportunities

• Strong presence of pipeline drugs
• Growth opportunities in emerging market

Market players

• The major players profiled in the report include Amgen Inc., AstraZeneca plc, F. Hoffmann-La Roche AG, AbbVie Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., and Sanofi S.A.

Key takeaways

• The study presents extensive analysis of the current and emerging market trends and dynamics in the global monoclonal antibody market to identify the prevailing opportunities
• It presents the competitive landscape of the global market to predict the competitive environment across the region
• Comprehensive analysis of factors that drive and restrict the market growth is provided.
• A region wise analysis is provided to understand the market trends and dynamics.

Market Landscape

• By Source
• Humanized & Human
• Chimeric
• Murine
• By Indication type
• Cancer
• Autoimmune Disease
• Inflammatory Diseases
• Neurology
• Others
• By Sales Channel
• Hospital Pharmacy
• Online Provider
• Retail Pharmacy
• By Region
• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA

Contents

SECTION 1 EXECUTIVE SUMMARY

1.1. COMPETITIVE LANDSCAPE AND RECENT INDUSTRY DEVELOPMENT ANALYSIS

SECTION 2 INTRODUCTION

2.1. REPORT DESCRIPTION
2.2. SCOPE AND DEFINITION
2.3. RESEARCH AND METHODOLOGY
  2.3.1. Secondary research
  2.3.2. Primary research
  2.3.3. Analyst tools and models

SECTION 3 MARKET LANDSCAPE

3.1. DRIVERS
  3.1.1. Increase in prevalence of cancer, autoinflammatory and autoimmune diseases across the globe
  3.1.2. Rise in demand for personalized therapeutics
  3.1.3. Rise in global geriatric population
3.2. RESTRAINTS AND CHALLENGES
  3.2.1. Higher cost of monoclonal antibody
  3.2.2. Adverse effects associated with the use of monoclonal antibodies
3.3. OPPORTUNITIES
  3.3.1. Potential monoclonal antibodies in pipeline
  3.3.2. Growth opportunities in the emerging markets
3.4. GLOBAL MONOCLONAL ANTIBODY MARKET SHARE ANALYSIS, 2014-2025
  3.4.1. Global monoclonal antibody market share, by source type, 2014-2025
  3.4.2. Global monoclonal antibody market share, by indication type, 2014-2025
  3.4.3. Global monoclonal antibody market share by sales channel, 2014-2025
  3.4.4. Global monoclonal antibody market share by geography, 2014-2025

SECTION 4 MONOCLONAL ANTIBODY MARKET, BY SOURCE TYPE

4.1. MURINE MONOCLONAL ANTIBODY
  4.1.1. Historical Market Size by Region, 2014-2016
  4.1.2. Market Forecast by Region, 2017-2025
4.2. CHIMERIC MONOCLONAL ANTIBODY
  4.2.1. Historical Market Size by Region, 2014-2016
  4.2.2. Market Forecast by Region, 2017-2025
4.3. HUMANIZED MONOCLONAL ANTIBODY
  4.3.1. Historical Market Size by Region, 2014-2016
  4.3.2. Market Forecast by Region, 2017-2025

SECTION 5 MONOCLONAL ANTIBODY MARKET, BY INDICATION TYPE

5.1. CANCER
  5.1.1. Market Forecast by Region, 2017-2025
5.2. AUTOIMMUNE DISEASES
  5.2.1. Market Forecast by Region, 2017-2025
5.3. AUTOINFLAMMATORY DISEASES
  5.3.1. Market Forecast by Region, 2017-2025
5.4. NEUROLOGIC DISEASES
  5.4.1. Market Forecast by Region, 2017-2025

SECTION 6 MONOCLONAL ANTIBODY MARKET, BY DISTRIBUTION CHANNEL TYPE

6.1. HOSPITAL PHARMACIES
  6.1.1. Market Forecast by Region, 2017-2025
6.2. ONLINE PHARMACIES
  6.2.1. Market Forecast by Region, 2017-2025
6.3. RETAIL PHARMACIES
  6.3.1. Market Forecast by Region, 2017-2025

SECTION 7 MONOCLONAL ANTIBODY MARKET, BY REGION

7.1. NORTH AMERICA
  7.1.1. U.S.
    7.1.1.1. Historical Market Size, 2014-2016
    7.1.1.2. Market Forecast, 2017-2025
  7.1.2. Canada
    7.1.2.1. Historical Market Size, 2014-2016
    7.1.2.2. Market Forecast, 2017-2025
  7.1.3. Mexico
    7.1.3.1. Historical Market Size, 2014-2016
    7.1.3.2. Market Forecast, 2017-2025
7.2. EUROPE
  7.2.1. UK
    7.2.1.1. Historical Market Size, 2014-2016
    7.2.1.2. Market Forecast, 2017-2025
  7.2.2. Germany
    7.2.2.1. Historical Market Size, 2014-2016
    7.2.2.2. Market Forecast, 2017-2025
  7.2.3. France
    7.2.3.1. Historical Market Size, 2014-2016
    7.2.3.2. Market Forecast, 2017-2025
  7.2.4. Italy
    7.2.4.1. Historical Market Size, 2014-2016
    7.2.4.2. Market Forecast, 2017-2025
  7.2.5. Spain
    7.2.5.1. Historical Market Size, 2014-2016
    7.2.5.2. Market Forecast, 2017-2025
  7.2.6. Rest of Europe
    7.2.6.1. Historical Market Size, 2014-2016
    7.2.6.2. Market Forecast, 2017-2025
7.3. ASIA-PACIFIC
  7.3.1. China
    7.3.1.1. Historical Market Size, 2014-2016
    7.3.1.2. Market Forecast, 2017-2025
  7.3.2. Japan
    7.3.2.1. Historical Market Size, 2014-2016
    7.3.2.2. Market Forecast, 2017-2025
  7.3.3. India
    7.3.3.1. Historical Market Size, 2014-2016
    7.3.3.2. Market Forecast, 2017-2025
  7.3.4. Australia
    7.3.4.1. Historical Market Size, 2014-2016
    7.3.4.2. Market Forecast, 2017-2025
  7.3.5. Rest of Asia-Pacific
    7.3.5.1. Historical Market Size, 2014-2016
    7.3.5.2. Market Forecast, 2017-2025
7.4. LAMEA
  7.4.1. Brazil
    7.4.1.1. Historical Market Size, 2014-2016
    7.4.1.2. Market Forecast, 2017-2025
  7.4.2. Saudi Arabia
    7.4.2.1. Historical Market Size, 2014-2016
    7.4.2.2. Market Forecast, 2017-2025
  7.4.3. South Africa
    7.4.3.1. Historical Market Size, 2014-2016
    7.4.3.2. Market Forecast, 2017-2025
  7.4.4. Rest of LAMEA
    7.4.4.1. Historical Market Size, 2014-2016
    7.4.4.2. Market Forecast, 2017-2025

SECTION 8 COMPANY PROFILES

8.1. ABBVIE INC.
  8.1.1. Company overview
  8.1.2. Business Performance
  8.1.3. Strategic moves and developments
  8.1.4. SWOT analysis of AbbVie Inc.
8.2. AMGEN
  8.2.1. Company overview
  8.2.2. Business performance
  8.2.3. Strategic moves and developments
  8.2.4. SWOT analysis of Amgen
8.3. ASTRAZENECA
  8.3.1. Overview
  8.3.2. Business performance
  8.3.3. Strategic moves and developments
  8.3.4. SWOT analysis of AstraZeneca
8.4. BRISTOL-MYERS SQUIBB
  8.4.1. Overview
  8.4.2. Products, Services, and Solutions
  8.4.3. Business performance
  8.4.4. Strategic moves and developments
  8.4.5. SWOT analysis of Bristol-Myers Squibb
8.5. F. HOFFMAN-LA ROCHE AG
  8.5.1. Overview
  8.5.2. Business performance
  8.5.3. Strategic moves and developments
  8.5.4. SWOT analysis of F. Hoffman-la Roche AG
8.6. JOHNSON & JOHNSON
  8.6.1. Overview
  8.6.2. Business performance
  8.6.3. Strategic moves and developments
  8.6.4. SWOT analysis of Johnson & Johnson
8.7. MERCK & CO., INC.
  8.7.1. Overview
  8.7.2. Business performance
  8.7.3. Strategic moves and developments
  8.7.4. SWOT analysis of Merck & Co., Inc.
8.8. NOVARTIS INTERNATIONAL AG
  8.8.1. Overview
  8.8.2. Business performance
  8.8.3. Strategic moves and developments
  8.8.4. SWOT analysis of Novartis International AG
8.9. PFIZER INC.
  8.9.1. Overview
  8.9.2. Business performance
  8.9.3. Strategic moves and developments
  8.9.4. SWOT analysis of Pfizer Inc.
8.10. SANOFI
  8.10.1. Overview
  8.10.2. Business performance
  8.10.3. Strategic moves and developments
  8.10.4. SWOT analysis of Sanofi

List Of Tables

LIST OF TABLES

TABLE 1. MONOCLONAL ANTIBODY MARKET REVENUE SHARE, BY SOURCE TYPE, 2014-2025 (%)
TABLE 2. MONOCLONAL ANTIBODY MARKET REVENUE SHARE, BY INDICATION, 2014-2025 (%)
TABLE 3. MONOCLONAL ANTIBODY MARKET REVENUE SHARE, BY SALES CHANNEL, 2014-2025 (%)
TABLE 4. MONOCLONAL ANTIBODY MARKET REVENUE SHARE, BY GEOGRAPHY, 2014-2025 (%)
TABLE 5. GLOBAL MONOCLONAL ANTIBODY MARKET, BY SOURCE TYPE, VALUE ($MILLION)
TABLE 6. GLOBAL MURINE MONOCLONAL ANTIBODY MARKET VALUE, BY GEOGRAPHY, ($MILLION)
TABLE 7. GLOBAL CHIMERIC MONOCLONAL ANTIBODY MARKET VALUE, BY GEOGRAPHY, ($MILLION)
TABLE 8. GLOBAL HUMANIZED MONOCLONAL ANTIBODY MARKET VALUE, BY GEOGRAPHY, ($MILLION)
TABLE 9. GLOBAL MONOCLONAL ANTIBODY MARKET VALUE, BY INDICATION TYPE ($MILLION)
TABLE 10. GLOBAL MONOCLONAL ANTIBODY MARKET FOR CANCER MARKET, BY GEOGRAPHY, ($MILLION)
TABLE 11. GLOBAL MONOCLONAL ANTIBODY MARKET VALUE, BY DISTRIBUTION CHANNEL TYPE, ($MILLION)
TABLE 12. GLOBAL HOSPITAL PHARMACIES MARKET VALUE, BY GEOGRAPHY, ($MILLION)
TABLE 13. GLOBAL ONLINE PHARMACIES MARKET VALUE, BY GEOGRAPHY, ($MILLION)
TABLE 14. GLOBAL RETAIL PHARMACIES MARKET VALUE, BY GEOGRAPHY, ($MILLION)
TABLE 15. MONOCLONAL ANTIBODY MARKET, BY REGION, 2014-2025, ($MILLION)
TABLE 16. GLOBAL MONOCLONAL ANTIBODY MARKET VALUE, BY COUNTRY, 2014-2025, ($MILLION)
TABLE 17. NORTH AMERICA MONOCLONAL ANTIBODY MARKET, BY SOURCE TYPE, ($MILLION)
TABLE 18. NORTH AMERICA MONOCLONAL ANTIBODY MARKET, BY INDICATION, ($MILLION)
TABLE 19. NORTH AMERICA MONOCLONAL ANTIBODY MARKET, BY SALES CHANNEL, ($MILLION)
TABLE 20. NORTH AMERICA MONOCLONAL ANTIBODY MARKET, BY COUNTRY, 2014-2025, ($MILLION)
TABLE 21. EUROPE MONOCLONAL ANTIBODY MARKET, BY SOURCE TYPE, ($MILLION)
TABLE 22. EUROPE MONOCLONAL ANTIBODY MARKET, BY INDICATION, ($MILLION)
TABLE 23. EUROPE MONOCLONAL ANTIBODY MARKET, BY SALES CHANNEL, ($MILLION)
TABLE 24. EUROPE MONOCLONAL ANTIBODY MARKET VALUE, BY COUNTRY, 2014-2025 ($MILLION)
TABLE 25. ASIA-PACIFIC MONOCLONAL ANTIBODY MARKET, BY SOURCE TYPE, ($MILLION)
TABLE 26. ASIA-PACIFIC MONOCLONAL ANTIBODY MARKET, BY INDICATION, ($MILLION)
TABLE 27. ASIA-PACIFIC MONOCLONAL ANTIBODY MARKET, BY SALES CHANNEL, ($MILLION)
TABLE 28. ASIA-PACIFIC MONOCLONAL ANTIBODY MARKET VALUE, BY COUNTRY, 2014-2025 ($MILLION)
TABLE 29. LAMEA MONOCLONAL ANTIBODY MARKET, BY SOURCE TYPE, ($MILLION)
TABLE 30. LAMEA MONOCLONAL ANTIBODY MARKET, BY INDICATION, ($MILLION)
TABLE 31. LAMEA MONOCLONAL ANTIBODY MARKET, BY SALES CHANNEL, ($MILLION)
TABLE 32. LAMEA MONOCLONAL ANTIBODY MARKET VALUE, BY COUNTRY, 2014-2025 ($MILLION)
TABLE 33. COMPANY SNAPSHOT, ABBVIE INC.
TABLE 34. COMPANY SNAPSHOT, AMGEN
TABLE 35. COMPANY SNAPSHOT, ASTRAZENECA
TABLE 36. COMPANY SNAPSHOT, BRISTOL-MYERS SQUIBB
TABLE 37. COMPANY SNAPSHOT, F. HOFFMAN-LA ROCHE AG
TABLE 38. COMPANY SNAPSHOT, JOHNSON & JOHNSON
TABLE 39. COMPANY SNAPSHOT, MERCK & CO., INC.
TABLE 40. COMPANY SNAPSHOT, NOVARTIS INTERNATIONAL
TABLE 41. COMPANY SNAPSHOT, PFIZER.
TABLE 42. COMPANY SNAPSHOT, SANOFI.

List Of Figures

LIST OF FIGURES

FIGURE 1. GLOBAL MONOCLONAL ANTIBODY MARKET SNAPSHOT
FIGURE 2. KEY FINDINGS
FIGURE 3. MAJOR STRATEGIES, 2013-2016 (%)
FIGURE 4. MAJOR STRATEGIES, BY COMPANY, 2013-2016
FIGURE 5. RESEARCH METHODOLOGY
FIGURE 6. GLOBAL MURINE MONOCLONAL ANTIBODY MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 7. GLOBAL CHIMERIC MONOCLONAL ANTIBODY MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 8. GLOBAL HUMANIZED MONOCLONAL ANTIBODY MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 9. GLOBAL MONOCLONAL ANTIBODY MARKET, 2014-2025
FIGURE 10. NORTH AMERICA MONOCLONAL ANTIBODY MARKET, 2014-2025
FIGURE 11. MONOCLONAL ANTIBODY MARKET: U.S. MARKET, 2014-2016 ($MILLION)
FIGURE 12. MONOCLONAL ANTIBODY MARKET: U.S. MARKET, 2017-2025 ($MILLION)
FIGURE 13. MONOCLONAL ANTIBODY MARKET: CANADA MARKET, 2014-2016 ($MILLION)
FIGURE 14. MONOCLONAL ANTIBODY MARKET: CANADA MARKET VALUE, 2017-2025 ($MILLION)
FIGURE 15. MONOCLONAL ANTIBODY MARKET: MEXICO MARKET, 2014-2016 ($MILLION)
FIGURE 16. MONOCLONAL ANTIBODY MARKET: MEXICO MARKET VALUE, 2017-2025 ($MILLION)
FIGURE 17. EUROPE MONOCLONAL ANTIBODY MARKET, 2014-2025
FIGURE 18. MONOCLONAL ANTIBODY MARKET: U.K. MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 19. MONOCLONAL ANTIBODY MARKET: U.K. MARKET, 2017-2025 ($MILLION)
FIGURE 20. MONOCLONAL ANTIBODY MARKET: GERMANY MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 21. MONOCLONAL ANTIBODY MARKET: GERMANY MARKET, 2017-2025 ($MILLION)
FIGURE 22. MONOCLONAL ANTIBODY MARKET: FRANCE MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 23. MONOCLONAL ANTIBODY MARKET: FRANCE MARKET, 2017-2025 ($MILLION)
FIGURE 24. MONOCLONAL ANTIBODY MARKET: ITALY MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 25. MONOCLONAL ANTIBODY MARKET: ITALY MARKET, 2017-2025 ($MILLION)
FIGURE 26. MONOCLONAL ANTIBODY MARKET: SPAIN MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 27. MONOCLONAL ANTIBODY MARKET: SPAIN MARKET, 2017-2025 ($MILLION)
FIGURE 28. MONOCLONAL ANTIBODY MARKET: REST OF EUROPE MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 29. MONOCLONAL ANTIBODY MARKET: REST OF EUROPE MARKET, 2017-2025 ($MILLION)
FIGURE 30. ASIA-PACIFIC MONOCLONAL ANTIBODY MARKET, 2014-2025
FIGURE 31. MONOCLONAL ANTIBODY MARKET: CHINA MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 32. MONOCLONAL ANTIBODY MARKET: CHINA MARKET, 2017-2025 ($MILLION)
FIGURE 33. MONOCLONAL ANTIBODY MARKET: JAPAN MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 34. MONOCLONAL ANTIBODY MARKET: JAPAN MARKET, 2017-2025 ($MILLION)
FIGURE 35. MONOCLONAL ANTIBODY MARKET: INDIA MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 36. MONOCLONAL ANTIBODY MARKET: INDIA MARKET, 2017-2025 ($MILLION)
FIGURE 37. MONOCLONAL ANTIBODY MARKET: AUSTRALIA MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 38. MONOCLONAL ANTIBODY MARKET: AUSTRALIA, 2017-2025 ($MILLION)
FIGURE 39. MONOCLONAL ANTIBODY MARKET: REST OF ASIA PACIFIC MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 40. MONOCLONAL ANTIBODY MARKET: REST OF ASIA-PACIFIC, 2017-2025 ($MILLION)
FIGURE 41. LAMEA MONOCLONAL ANTIBODY MARKET, 2014-2025
FIGURE 42. MONOCLONAL ANTIBODY MARKET: BRAZIL MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 43. MONOCLONAL ANTIBODY MARKET: BRAZIL MARKET, 2017-2025 ($MILLION)
FIGURE 44. MONOCLONAL ANTIBODY MARKET: SAUDI ARABIA MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 45. MONOCLONAL ANTIBODY MARKET: SAUDI ARABIA MARKET, 2017-2025 ($MILLION)
FIGURE 46. MONOCLONAL ANTIBODY MARKET: SOUTH AFRICA MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 47. MONOCLONAL ANTIBODY MARKET: SOUTH AFRICA, 2017-2025 ($MILLION)
FIGURE 48. MONOCLONAL ANTIBODY MARKET: REST OF LAMEA MARKET VALUE, 2014-2016 ($MILLION)
FIGURE 49. MONOCLONAL ANTIBODY MARKET: REST OF LAMEA, 2017-2025 ($MILLION)
FIGURE 50. ABBVIE INC.: BUSINESS PERFORMANCE
FIGURE 51. ABBVIE INC.: SWOT ANALYSIS
FIGURE 52. AMGEN: BUSINESS PERFORMANCE
FIGURE 53. AMGEN: SWOT ANALYSIS
FIGURE 54. ASTRAZENECA: BUSINESS PERFORMANCE
FIGURE 55. ASTRAZENECA: SWOT ANALYSIS
FIGURE 56. BRISTOL-MYERS SQUIBB: BUSINESS PERFORMANCE
FIGURE 57. BRISTOL-MYERS SQUIBB: SWOT ANALYSIS
FIGURE 58. F. HOFFMAN-LA ROCHE AG: BUSINESS PERFORMANCE
FIGURE 59. F. HOFFMAN-LA ROCHE AG: SWOT ANALYSIS
FIGURE 60. JOHNSON & JOHNSON: BUSINESS PERFORMANCE
FIGURE 61. JOHNSON & JOHNSON: SWOT ANALYSIS
FIGURE 62. MERCK & CO., INC.: BUSINESS PERFORMANCE
FIGURE 63. MERCK & CO., INC. LIMITED: SWOT ANALYSIS
FIGURE 64. NOVARTIS INTERNATIONAL AG: BUSINESS PERFORMANCE
FIGURE 65. NOVARTIS INTERNATIONAL AG: SWOT ANALYSIS
FIGURE 66. PFIZER INC.: BUSINESS PERFORMANCE
FIGURE 67. PFIZER INC.: SWOT ANALYSIS
FIGURE 68. SANOFI: BUSINESS PERFORMANCE
FIGURE 69. SANOFI: SWOT ANALYSIS